Who's the WHO?, page-31

I don't see FDA as the end game.

In fact, FDA is not required to turn this stock into a billion dollar plus company. It just helps or accelerates this process.

With proven results, China alone would triple the US market.

remember, an App is not a food nor a drug, it's a diagnostic tool, so telehealth providers world wide, including the US could use it without FDA approval.

RAP needs to put all its focus into completing the US and Australian trials, forget any expansions, (and awards) and bring a product to market. Once we have a company with steady revenue, then efforts to expand ResApps repertoire of functions can be developed.